Galena Biopharma, a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, and Dr. Reddy's Laboratories, an integrated global pharmaceutical company, have announced a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India.

"This partnership with Dr. Reddy's is consistent with our strategy to expand the clinical utility of NeuVax in unmet medical needs while simultaneously increasing the commercial footprint of this innovative cancer immunotherapy," said Mark J. Ahn, Ph.D., president and CEO of Galena Biopharma. "Dr. Reddy's is a pharmaceutical company in India with significant commercialization and development experience. The gastric cancer trial will add a significant indication to our pipeline for NeuVax, while doubling our potential patient population if approved."